Cargando…
Targeting Complement C5a Receptor 1 for the Treatment of Immunosuppression in Sepsis
Complement factor C5a was originally identified as a powerful promoter of inflammation through activation of the C5a receptor 1 (C5ar1). Recent evidence suggests involvement of C5a not only in pro- but also in anti-inflammatory signaling. The present study aims to unveil the role of C5ar1 as potenti...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society of Gene & Cell Therapy
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7791006/ https://www.ncbi.nlm.nih.gov/pubmed/32966769 http://dx.doi.org/10.1016/j.ymthe.2020.09.008 |
_version_ | 1783633520880517120 |
---|---|
author | Sommerfeld, Oliver Medyukhina, Anna Neugebauer, Sophie Ghait, Mohamed Ulferts, Svenja Lupp, Amelie König, Rainer Wetzker, Reinhard Schulz, Stefan Figge, Marc Thilo Bauer, Michael Press, Adrian T. |
author_facet | Sommerfeld, Oliver Medyukhina, Anna Neugebauer, Sophie Ghait, Mohamed Ulferts, Svenja Lupp, Amelie König, Rainer Wetzker, Reinhard Schulz, Stefan Figge, Marc Thilo Bauer, Michael Press, Adrian T. |
author_sort | Sommerfeld, Oliver |
collection | PubMed |
description | Complement factor C5a was originally identified as a powerful promoter of inflammation through activation of the C5a receptor 1 (C5ar1). Recent evidence suggests involvement of C5a not only in pro- but also in anti-inflammatory signaling. The present study aims to unveil the role of C5ar1 as potential therapeutic target in a murine sepsis model. Our study discloses a significantly increased survival in models of mild to moderate but not severe sepsis of C5ar1-deficient mice. The decreased mortality of C5ar1-deficient mice is accompanied by improved pathogen clearance and largely preserved liver function. C5ar1-deficient mice exhibited a significantly increased production of the pro-inflammatory mediator interferon-γ (IFN-γ) and a decreased production of the anti-inflammatory cytokine interleukin-10 (IL-10). Together, these data uncover C5a signaling as a mediator of immunosuppressive processes during sepsis and describe the C5ar1 and related changes of the IFN-γ to IL-10 ratio as markers for the immunological (dys)function accompanying sepsis. |
format | Online Article Text |
id | pubmed-7791006 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | American Society of Gene & Cell Therapy |
record_format | MEDLINE/PubMed |
spelling | pubmed-77910062022-01-06 Targeting Complement C5a Receptor 1 for the Treatment of Immunosuppression in Sepsis Sommerfeld, Oliver Medyukhina, Anna Neugebauer, Sophie Ghait, Mohamed Ulferts, Svenja Lupp, Amelie König, Rainer Wetzker, Reinhard Schulz, Stefan Figge, Marc Thilo Bauer, Michael Press, Adrian T. Mol Ther Original Article Complement factor C5a was originally identified as a powerful promoter of inflammation through activation of the C5a receptor 1 (C5ar1). Recent evidence suggests involvement of C5a not only in pro- but also in anti-inflammatory signaling. The present study aims to unveil the role of C5ar1 as potential therapeutic target in a murine sepsis model. Our study discloses a significantly increased survival in models of mild to moderate but not severe sepsis of C5ar1-deficient mice. The decreased mortality of C5ar1-deficient mice is accompanied by improved pathogen clearance and largely preserved liver function. C5ar1-deficient mice exhibited a significantly increased production of the pro-inflammatory mediator interferon-γ (IFN-γ) and a decreased production of the anti-inflammatory cytokine interleukin-10 (IL-10). Together, these data uncover C5a signaling as a mediator of immunosuppressive processes during sepsis and describe the C5ar1 and related changes of the IFN-γ to IL-10 ratio as markers for the immunological (dys)function accompanying sepsis. American Society of Gene & Cell Therapy 2021-01-06 2020-09-05 /pmc/articles/PMC7791006/ /pubmed/32966769 http://dx.doi.org/10.1016/j.ymthe.2020.09.008 Text en © 2020 The Authors http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
spellingShingle | Original Article Sommerfeld, Oliver Medyukhina, Anna Neugebauer, Sophie Ghait, Mohamed Ulferts, Svenja Lupp, Amelie König, Rainer Wetzker, Reinhard Schulz, Stefan Figge, Marc Thilo Bauer, Michael Press, Adrian T. Targeting Complement C5a Receptor 1 for the Treatment of Immunosuppression in Sepsis |
title | Targeting Complement C5a Receptor 1 for the Treatment of Immunosuppression in Sepsis |
title_full | Targeting Complement C5a Receptor 1 for the Treatment of Immunosuppression in Sepsis |
title_fullStr | Targeting Complement C5a Receptor 1 for the Treatment of Immunosuppression in Sepsis |
title_full_unstemmed | Targeting Complement C5a Receptor 1 for the Treatment of Immunosuppression in Sepsis |
title_short | Targeting Complement C5a Receptor 1 for the Treatment of Immunosuppression in Sepsis |
title_sort | targeting complement c5a receptor 1 for the treatment of immunosuppression in sepsis |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7791006/ https://www.ncbi.nlm.nih.gov/pubmed/32966769 http://dx.doi.org/10.1016/j.ymthe.2020.09.008 |
work_keys_str_mv | AT sommerfeldoliver targetingcomplementc5areceptor1forthetreatmentofimmunosuppressioninsepsis AT medyukhinaanna targetingcomplementc5areceptor1forthetreatmentofimmunosuppressioninsepsis AT neugebauersophie targetingcomplementc5areceptor1forthetreatmentofimmunosuppressioninsepsis AT ghaitmohamed targetingcomplementc5areceptor1forthetreatmentofimmunosuppressioninsepsis AT ulfertssvenja targetingcomplementc5areceptor1forthetreatmentofimmunosuppressioninsepsis AT luppamelie targetingcomplementc5areceptor1forthetreatmentofimmunosuppressioninsepsis AT konigrainer targetingcomplementc5areceptor1forthetreatmentofimmunosuppressioninsepsis AT wetzkerreinhard targetingcomplementc5areceptor1forthetreatmentofimmunosuppressioninsepsis AT schulzstefan targetingcomplementc5areceptor1forthetreatmentofimmunosuppressioninsepsis AT figgemarcthilo targetingcomplementc5areceptor1forthetreatmentofimmunosuppressioninsepsis AT bauermichael targetingcomplementc5areceptor1forthetreatmentofimmunosuppressioninsepsis AT pressadriant targetingcomplementc5areceptor1forthetreatmentofimmunosuppressioninsepsis |